The 6 most recent market catalysts affecting $OSTX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 65
OS Therapies Achieves Incremental FDA Alignment Regarding Its Biologics License Application For OST-HER2 For Prevention Or Delay Of Recurrence In Fully-Resected, Pulmonary Metastatic Osteosarcoma
OS Therapies has achieved significant regulatory milestones for its OST-HER2 therapy. The FDA's alignment on the Phase 3 trial design, coupled with MHRA's commitment to lead the co…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 85
OS Therapies Achieves Full Alignment With UK MHRA On Its Pending Conditional Marketing Authorization Application
OS Therapies announced full alignment with the UK MHRA on its Conditional Marketing Authorization Application (CMAA) for OST-HER2, an important step for its osteosarcoma treatment.…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 75
OS Therapies Reports Strong Survival Data for Bone Cancer Treatment
OS Therapies (OSTX) reported highly encouraging interim Phase 2b data for its OST-HER2 therapy, demonstrating a 71.2% overall survival rate at three years compared to a 45.8% histo…
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 65
OS Therapies Enters Open Market Sale Agreement With Jefferies; May Offer Common Stock Up To $75M Through Jefferies
OS Therapies has established an At-The-Market (ATM) equity offering program with Jefferies, enabling them to sell up to $75 million in common stock. This is a common financing stra…
Aug 13, 2026
Corporate Catalyst
Neutral
Impact 75
FDA Grants OS Therapies’ Requested Type C Statistical Methods Meeting To Review 2.5-Yr Overall Survival Data From Phase 2b Trial Of OST-HER2 In Prevention Of Recurrence In Pulmonary Metastatic Osteosarcoma; Meeting To Occur In Mid-September
OS Therapies (OSTX) announced that the FDA has granted a Type C Statistical Methods meeting for its OST-HER2 therapy, scheduled for mid-September 2026. This meeting is a significan…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 55
OS Therapies Terminates At Market Issuance Sales Agreement On July 23; Co. Announces Termination Of Sales Agreement Effective July 28
OS Therapies has terminated its At Market Issuance Sales Agreement. This type of agreement allows a company to sell newly issued shares into the open market over time, providing a …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.